32.17
前日終値:
$30.07
開ける:
$31.37
24時間の取引高:
658.24K
Relative Volume:
0.91
時価総額:
$2.19B
収益:
$87.56M
当期純損益:
$-167.47M
株価収益率:
-13.75
EPS:
-2.34
ネットキャッシュフロー:
$-148.20M
1週間 パフォーマンス:
-4.20%
1か月 パフォーマンス:
+33.37%
6か月 パフォーマンス:
-35.66%
1年 パフォーマンス:
-15.12%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
KYMR
Kymera Therapeutics Inc
|
32.17 | 2.19B | 87.56M | -167.47M | -148.20M | -2.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-13 | 開始されました | Citigroup | Buy |
2024-12-10 | 開始されました | BTIG Research | Buy |
2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2024-11-18 | 開始されました | Stephens | Overweight |
2024-09-09 | 再開されました | Leerink Partners | Outperform |
2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2024-04-22 | 開始されました | Oppenheimer | Outperform |
2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2023-06-30 | 開始されました | Truist | Buy |
2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
2022-11-08 | 開始されました | Raymond James | Mkt Perform |
2022-08-15 | 開始されました | Jefferies | Buy |
2022-08-03 | 開始されました | Goldman | Buy |
2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
2022-04-28 | 開始されました | Credit Suisse | Outperform |
2022-03-10 | 開始されました | JP Morgan | Neutral |
2022-02-10 | 開始されました | Wells Fargo | Overweight |
2021-09-30 | 開始されました | B. Riley Securities | Neutral |
2021-09-30 | 開始されました | Stifel | Buy |
2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
2021-05-21 | 開始されました | UBS | Buy |
2021-04-14 | 開始されました | Berenberg | Buy |
2020-12-04 | 開始されました | H.C. Wainwright | Buy |
2020-09-15 | 開始されました | BofA Securities | Neutral |
2020-09-15 | 開始されました | Cowen | Outperform |
2020-09-15 | 開始されました | Guggenheim | Buy |
2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga
Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from Guggenheim | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus
Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus
Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK
Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech
B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com
BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus
Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Kymera advances oral drug for autoimmune diseases - Investing.com
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus
Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India
Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com
Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus
Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks
Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus
Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus
Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus
Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks
Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa
Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada
Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus
Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Strong Q1 Performance | KYMR Stock News - GuruFocus
Kymera Therapeutics Introduces KT-579 Targeting IRF5 - TipRanks
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update | KYMR Stock News - GuruFocus
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update - The Manila Times
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases - The Manila Times
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases | KYMR Stock News - GuruFocus
Kymera Therapeutics Advances Oral Immunology Pipeline with Promising New Program Targeting IRF5 for Autoimmune Diseases - Nasdaq
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire Inc.
What's Next: Kymera Therapeutics's Earnings Preview - Nasdaq
What To Expect From Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings - GuruFocus
Dimensional Fund Advisors LP Sells 38,871 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
KYMERA THERAPEUTICS Earnings Preview: Recent $KYMR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference - The Manila Times
Kymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Friday - Defense World
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $56.36 - Defense World
Kymera Therapeutics Inc’s results are impressive - uspostnews.com
Market Momentum Report: Kymera Therapeutics Inc (KYMR)’s Positive Close at 34.55 - DWinneX
Invesco Ltd. Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Wells Fargo & Company MN Acquires 7,487 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):